Sujet

Maladies cardiaques

Cardiovascular health, heart failure, atherosclerosis, and cardiac research

414 articles

Bempedoic Acid Cuts Venous Clot Risk by 42% in Statin-Intolerant Patients
Heart Health

Bempedoic Acid Cuts Venous Clot Risk by 42% in Statin-Intolerant Patients

A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.

Article de recherche
29 mai 2026 0
Climate Change and Aging Are Driving a Cardiovascular Crisis Together
Heart Health

Climate Change and Aging Are Driving a Cardiovascular Crisis Together

A new JAMA Cardiology analysis warns that rising temperatures and a growing elderly population are converging to produce an unprecedented cardiac emergency.

Article de recherche
29 mai 2026 0
REGENXBIO Hunts LDLR Mutations to Build a Gene Therapy Pipeline for Rare Cholesterol Disorder
Heart Health

REGENXBIO Hunts LDLR Mutations to Build a Gene Therapy Pipeline for Rare Cholesterol Disorder

A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.

Essai clinique
28 mai 2026 0
PCSK9 Inhibitor AK102 Tested Against High-Risk Hypercholesterolemia in Phase 2 Trial
Heart Health

PCSK9 Inhibitor AK102 Tested Against High-Risk Hypercholesterolemia in Phase 2 Trial

Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.

Essai clinique
27 mai 2026 0
Pelacarsen Targets Lp(a) in Black and Hispanic Americans With Heart Disease
Heart Health

Pelacarsen Targets Lp(a) in Black and Hispanic Americans With Heart Disease

A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.

Essai clinique
27 mai 2026 0
Indoor Cycling Three Times a Week Targets CVD Risk Factors in Women With Obesity
Heart Health

Indoor Cycling Three Times a Week Targets CVD Risk Factors in Women With Obesity

A 3-month interval cycling program assessed cardiovascular and metabolic improvements in obese vs. normal-weight women.

Essai clinique
27 mai 2026 0
Anticoagulation Clinics Show How to Manage Heart Medications Smarter
Heart Health

Anticoagulation Clinics Show How to Manage Heart Medications Smarter

Experts propose that structured anticoagulation services offer a blueprint for broader cardiovascular medication stewardship programs.

Article de recherche
27 mai 2026 0
2025 AHA/ACC Hypertension Guidelines Get Official Correction Update
Heart Health

2025 AHA/ACC Hypertension Guidelines Get Official Correction Update

A formal correction is issued to the landmark 2025 multi-society hypertension guidelines, ensuring clinical accuracy for practitioners.

Article de recherche
27 mai 2026 0
Breast Cancer Treatment Uncovers Hidden BMPR2 Risk for Pulmonary Hypertension
Heart Health

Breast Cancer Treatment Uncovers Hidden BMPR2 Risk for Pulmonary Hypertension

A correction to a landmark study linking breast cancer to latent BMPR2-driven pulmonary hypertension susceptibility in Circulation.

Article de recherche
27 mai 2026 0
Major Trial Finds Beta Blockers After Heart Attack Offer No Benefit for Most Patients
Heart Health

Major Trial Finds Beta Blockers After Heart Attack Offer No Benefit for Most Patients

A landmark 8,500-patient trial challenges 40 years of cardiology practice, finding beta blockers unnecessary after uncomplicated heart attacks.

Communiqué de presse
26 mai 2026 0
Phase 3 Trial Tests Omecamtiv Mecarbil for Reducing Death in Heart Failure Patients
Heart Health

Phase 3 Trial Tests Omecamtiv Mecarbil for Reducing Death in Heart Failure Patients

A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.

Essai clinique
26 mai 2026 0
Merck's Niacin-Laropiprant Cholesterol Trial Terminated Before Completion
Heart Health

Merck's Niacin-Laropiprant Cholesterol Trial Terminated Before Completion

A phase 3 trial adding ERN/LRPT to statin therapy for dyslipidemia was terminated early, raising questions about the drug's clinical future.

Essai clinique
26 mai 2026 0
PreviousPage 6 of 35Next